1M.D. Anderson Cancer Center, Houston, TX [email protected]
2Dana–Farber Cancer Institute, Boston, MA
Dr. Pemmaraju reports receiving research funding or clinical trial support from Stemline Therapeutics, Novartis, Samus Therapeutics, AbbVie, Cellectis, Plexxikon, Daiichi Sankyo, and Affymetrix and consulting fees from Novartis, Incyte, LFB, and Celgene; Dr. Konopleva, receiving research funding from AbbVie, Genentech, Eli Lilly, Cellectis, Calithera Biosciences, Stemline Therapeutics, Threshold Pharmaceuticals, Flexus Biosciences, Novartis, Ablynx, and Agios Pharmaceuticals, consulting fees and honoraria from AbbVie, Genentech, and F. Hoffmann–La Roche, and advisory board fees from F. Hoffmann–La Roche and owning stock in Reata Pharmaceuticals; and Dr. Lane, receiving research funding from Stemline Therapeutics and AbbVie and consulting fees from N-of-One. No other potential conflict of interest relevant to this letter was reported.
